On May 9, 2025, Apellis Pharmaceuticals (APLS, Financial) faced a notable shift in analyst sentiment as Raymond James, through analyst Ryan Deschner, downgraded the company's rating. The rating moved from a previous 'Strong Buy' to 'Outperform'. This change reflects a recalibrated outlook on the company's near-term performance.
In addition to the downgrade, Raymond James also adjusted the price target for Apellis Pharmaceuticals (APLS, Financial). The price target was lowered significantly from $75.00 to $52.00 USD, marking a decrease of approximately 30.67%. This reduction indicates a more cautious stance on the potential growth and valuation of APLS shares in the current market environment.
The downgrade and revised price target come during a period of broader market analysis and sector evaluation. Investors in Apellis Pharmaceuticals (APLS, Financial) will need to consider these changes in their investment decisions, particularly in light of the new guidance from Raymond James.
Stay tuned for further market updates and insights on Apellis Pharmaceuticals (APLS, Financial) as the company navigates these recent developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for Apellis Pharmaceuticals Inc (APLS, Financial) is $37.85 with a high estimate of $75.00 and a low estimate of $18.00. The average target implies an upside of 115.67% from the current price of $17.55. More detailed estimate data can be found on the Apellis Pharmaceuticals Inc (APLS) Forecast page.
Based on the consensus recommendation from 23 brokerage firms, Apellis Pharmaceuticals Inc's (APLS, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Apellis Pharmaceuticals Inc (APLS, Financial) in one year is $188.59, suggesting a upside of 974.59% from the current price of $17.55. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Apellis Pharmaceuticals Inc (APLS) Summary page.
